Low-dose Radiotherapy Combined With Conventional Radiotherapy After Immunotherapy Failure

A Clinical Study of Low-dose Radiotherapy Combined With Conventional Radiotherapy in Patients With Malignant Tumors After Immunotherapy Failure

Response was evaluated according to the Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics (iRECIST) : ORR-To evaluate the objective effective rate of LDRT combined with SFRT and immunotherapy in patients with malignant tumors after immunotherapy resistance without standard regimens. PFS-To evaluate the progression-free survival (PFS) of patients with advanced malignant tumors after LDRT combined with SFRT and immunotherapy without standard regimens after immunotherapy resistance.DCR-To evaluate the proportion of patients with optimal response to LDRT and SFRT combined with immunotherapy to achieve complete response, partial response, or disease control after no standard regimen was available for immunotherapy resistance.HRQoL, AE and sAE-Evaluation of health related quality of life and safety of post-LDRT combined with SFRT and immunotherapy in patients with malignant tumors. To evaluate the benefit of patients in this trial.

Inclusion Criteria:

• 1. The patient understood, participated voluntarily and signed the informed consent

  2. Age 18-65

  3. Cytologically or histologically confirmed malignancy

  4. Complete clinical data

  5. The number of primary and regional metastatic lymph nodes and distant metastatic lesions was ≤10, and the number of organ metastases was ≤5.

  6. Patients with malignant tumors who are resistant to immunotherapy (the patient's disease progression is evaluated after 6-8 weeks of treatment without improvement of clinical symptoms), and no standard treatment options are available.

  7. Measurable primary lesions and regions

Exclusion Criteria:

• 1. Missing key patient data

  2. Refusing or not cooperating with the study

  3. Patients who have participated in other clinical studies/trials within 3 months

  4. Patients with brain metastases

  5. Patients with any conditions that the investigator judged to be ineligible for study participation

  6. Patients with uncontrolled severe medical diseases who cannot tolerate radiotherapy

  7. Past immune-related side effects (immune myocarditis, pneumonia, etc.)

  8. Previous history of radiation therapy